QTL Biosystems Lightspeed and EMD Biosciences Signal Transduction Interactive Pathways | GenomeWeb

QTL Biosystems has announced four new additions to its Lightspeed fluorescence-based kinase and protease assays: PKC-alpha (diabetes and leukemia screening), Akt-1 (cancer), Src (cancer), and p38-alpha (leukemia and lymphoma). QTL said the homogenous assays, which can be read with most commercially available fluorescence spectrometers and multiwell plate readers, are scalable from 96- to 3,456-well formats, and feature limits of detection in the picomolar range.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.